Switch theme
Sign up to access all valuation multiples
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue.
2010
11K+
LTM Revenue $4.3B
LTM EBITDA -$142M
$26.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BeiGene has a last 12-month revenue (LTM) of $4.3B and a last 12-month EBITDA of -$142M.
In the most recent fiscal year, BeiGene achieved revenue of $486M and an EBITDA of -$50.6M.
BeiGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BeiGene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.3B | XXX | $486M | XXX | XXX | XXX |
| Gross Profit | $3.7B | XXX | $410M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | -$142M | XXX | -$50.6M | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -10% | XXX | XXX | XXX |
| EBIT | -$282M | XXX | -$72.5M | XXX | XXX | XXX |
| EBIT Margin | -7% | XXX | -15% | XXX | XXX | XXX |
| Net Profit | -$325M | XXX | -$82.3M | XXX | XXX | XXX |
| Net Margin | -8% | XXX | -17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BeiGene's stock price is HKD 159 (or $20).
BeiGene has current market cap of HKD 223B (or $28.5B), and EV of HKD 211B (or $26.9B).
See BeiGene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.9B | $28.5B | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BeiGene has market cap of $28.5B and EV of $26.9B.
BeiGene's trades at 55.4x EV/Revenue multiple, and -532.5x EV/EBITDA.
Equity research analysts estimate BeiGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BeiGene has a P/E ratio of -87.7x.
See valuation multiples for BeiGene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28.5B | XXX | $28.5B | XXX | XXX | XXX |
| EV (current) | $26.9B | XXX | $26.9B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 55.4x | XXX | XXX | XXX |
| EV/EBITDA | -189.9x | XXX | -532.5x | XXX | XXX | XXX |
| EV/EBIT | -95.5x | XXX | -371.5x | XXX | XXX | XXX |
| EV/Gross Profit | 7.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -87.7x | XXX | -345.9x | XXX | XXX | XXX |
| EV/FCF | -78.8x | XXX | -315.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBeiGene's last 12 month revenue growth is 28%
BeiGene's revenue per employee in the last FY averaged $44K, while opex per employee averaged $44K for the same period.
BeiGene's rule of 40 is -18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BeiGene's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BeiGene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 255% | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | -438% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -18% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 99% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BeiGene acquired XXX companies to date.
Last acquisition by BeiGene was XXXXXXXX, XXXXX XXXXX XXXXXX . BeiGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BeiGene founded? | BeiGene was founded in 2010. |
| Where is BeiGene headquartered? | BeiGene is headquartered in Hong Kong. |
| How many employees does BeiGene have? | As of today, BeiGene has 11K+ employees. |
| Who is the CEO of BeiGene? | BeiGene's CEO is Mr. John V. Oyler. |
| Is BeiGene publicy listed? | Yes, BeiGene is a public company listed on HKG. |
| What is the stock symbol of BeiGene? | BeiGene trades under 06160 ticker. |
| When did BeiGene go public? | BeiGene went public in 2018. |
| Who are competitors of BeiGene? | Similar companies to BeiGene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BeiGene? | BeiGene's current market cap is $28.5B |
| What is the current revenue of BeiGene? | BeiGene's last 12 months revenue is $4.3B. |
| What is the current revenue growth of BeiGene? | BeiGene revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of BeiGene? | Current revenue multiple of BeiGene is 6.3x. |
| Is BeiGene profitable? | Yes, BeiGene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BeiGene? | BeiGene's last 12 months EBITDA is -$142M. |
| What is BeiGene's EBITDA margin? | BeiGene's last 12 months EBITDA margin is -3%. |
| What is the current EV/EBITDA multiple of BeiGene? | Current EBITDA multiple of BeiGene is -189.9x. |
| What is the current FCF of BeiGene? | BeiGene's last 12 months FCF is -$342M. |
| What is BeiGene's FCF margin? | BeiGene's last 12 months FCF margin is -8%. |
| What is the current EV/FCF multiple of BeiGene? | Current FCF multiple of BeiGene is -78.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
